Targeting Leukocyte Trafficking in Inflammatory Bowel Disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) involves chronic inflammation in the gastrointestinal tract.
• Understanding IBD immunopathogenesis has significantly advanced, revealing immune cell infiltration in the intestinal mucosa.

Purpose of the Study:

• To review established and emerging therapies targeting leukocyte trafficking for IBD.
• To explore gut-selective treatments that avoid systemic immunosuppression and its associated risks.

Main Methods:

• Review of scientific literature on immune cell trafficking mechanisms in IBD.
• Analysis of therapies targeting integrins, mucosal addressin cellular adhesion molecule-1, and sphingosine-1-phosphate receptors.

Main Results:

• Vedolizumab, an anti-integrin therapy, was the first approved gut-selective IBD treatment.
• Several novel anti-integrin drugs and other trafficking inhibitors are in development.

Conclusions:

• Targeting leukocyte trafficking offers promising gut-selective therapeutic strategies for IBD.
• These approaches are crucial for advancing precision medicine in IBD patient care.